Finding a Killer's Achilles' Heel: Clues from a Pandemic

The 1918 flu genome may help fight future outbreaks

Join Our Community of Science Lovers!


On supporting science journalism

If you're enjoying this article, consider supporting our award-winning journalism by subscribing. By purchasing a subscription you are helping to ensure the future of impactful stories about the discoveries and ideas shaping our world today.


It has been five years since a team of scientists resurrected the 1918 influenza virus from the lungs of a long-frozen victim. At the time, the Jurassic Park–like feat was both widely celebrated and sharply criticized. Opponents worried about the risk of an accidental (or intentional) release of the revived killer, which claimed between 50 million and 100 million lives in about 15 months and has been dubbed the worst plague in human history. Proponents insisted that the insights gained from a fully reconstructed virus would be instrumental in fighting the next pandemic.

A paper published in the November issue of the journal Microbe cites a potential new drug target, among other findings, as evidence that the risk was not taken in vain. Terrence Tumpey of the Centers for Disease Control and Prevention and his colleagues have closed in on a protein called PB1 that enables the virus to copy itself. When researchers substituted the PB1 protein in a normal flu virus with the 1918 version of that same protein, the normal virus morphed into a superkiller: it replicated and spread through its rodent host eight times faster, killing more mice as a result. It turns out that all 20th-century pandemic viruses, among them the 2009 swine flu, have avian flu PB1 genes. Most seasonal flu viruses have human flu PB1 genes.

Scientists are now working to develop new drugs that target PB1. Small molecules that bind to the protein’s receptors could prevent the virus from replicating and might greatly reduce virulence. The need for new antiflu drugs is increasingly urgent, as several recent flu strains, including the swine flu, have developed resistance to currently available treatments such as Tami­flu. When combined with the older antivirals, PB1-targeted drugs could drastically reduce the spread of resistance, making the approach of the annual flu season a little less worrisome for everyone.

Jeneen Interlandi is a New York City–based journalist who writes about health, science and the environment.

More by Jeneen Interlandi
Scientific American Magazine Vol 303 Issue 5This article was published with the title “Finding a Killer's Achilles' Heel: Clues from a Pandemic” in Scientific American Magazine Vol. 303 No. 5 ()
doi:10.1038/scientificamerican112010-5sWip1LSIjEjDudfQOmB95

It’s Time to Stand Up for Science

If you enjoyed this article, I’d like to ask for your support. Scientific American has served as an advocate for science and industry for 180 years, and right now may be the most critical moment in that two-century history.

I’ve been a Scientific American subscriber since I was 12 years old, and it helped shape the way I look at the world. SciAm always educates and delights me, and inspires a sense of awe for our vast, beautiful universe. I hope it does that for you, too.

If you subscribe to Scientific American, you help ensure that our coverage is centered on meaningful research and discovery; that we have the resources to report on the decisions that threaten labs across the U.S.; and that we support both budding and working scientists at a time when the value of science itself too often goes unrecognized.

In return, you get essential news, captivating podcasts, brilliant infographics, can't-miss newsletters, must-watch videos, challenging games, and the science world's best writing and reporting. You can even gift someone a subscription.

There has never been a more important time for us to stand up and show why science matters. I hope you’ll support us in that mission.

Thank you,

David M. Ewalt, Editor in Chief, Scientific American

Subscribe